Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius AGSARTF 83 EV-to-EBITDA is 18.74 as of Jul. 25, 2026, which is 19% below its 10-year median of 23.12. GuruFocus rates SARTF with a GF Score™ of 83/100 and a GF Value™ of $248.02 (Fairly Valued). The stock has 6 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Sartorius AG ranks worse than 66.27% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sartorius AG's enterprise value is $21,293 Mil.
Sartorius AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $1,136 Mil. Therefore, Sartorius AG's EV-to-EBITDA for today is 18.74.
The historical rank and industry rank for Sartorius AG's EV-to-EBITDA or its related term are showing as below:
SARTF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.67 Med: 23.12 Max: 61.11
Current: 18.99
During the past 13 years, the highest EV-to-EBITDA of Sartorius AG was 61.11. The lowest was 8.67. And the median was 23.12.
SARTF's EV-to-EBITDA is ranked worse than 66.27% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.845
vs SARTF: 18.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Sartorius AG (OTCPK:SARTF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sartorius AG's PE Ratio (TTM) for today is calculated as:
Sartorius AG's share price for today is $212.80.
Sartorius AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.349.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sartorius AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sartorius AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sartorius AG's EV-to-EBITDA falls into.
Sartorius AG's current Enterprise Value is $21,293 Mil.
Sartorius AG's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,136 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius AG (SARTF) has a EV-to-EBITDA of 18.74 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sartorius AG. This is 19% below median its historical median of 23.12. Over the past decade, Sartorius AG's EV-to-EBITDA has ranged from 8.67 to 61.11. According to the industry distribution chart, Sartorius AG ranks #338 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 66.3%.
Is Sartorius AG's EV-to-EBITDA too high?
Sartorius AG's current EV-to-EBITDA of 18.74 is 19% below median its 10-year median of 23.12. Over the past 10 years, this metric has ranged from a low of 8.67 to a high of 61.11. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.85. Sartorius AG's value of 18.74 is 35.4% above this industry median. Based on the distribution chart, Sartorius AG ranks #338 out of 510 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sartorius AG has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #338 out of 510 companies for EV-to-EBITDA. This places Sartorius AG in the lower half of its industry. The industry median EV-to-EBITDA is 13.85. Sartorius AG's value of 18.74 is 35.4% above this benchmark. Historically, Sartorius AG's own EV-to-EBITDA has ranged from 8.67 to 61.11 over the past decade. While the company's 10-year median is 23.12 vs. the industry median of 13.85, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.85, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current EV-to-EBITDA of 18.74 is 35.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sartorius AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current EV-to-EBITDA is 18.74, which is 19% below median its own 10-year median of 23.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Fairly Valued. The stock's GF Value™ is $248.02, compared to a current price of $212.80 — trading 14.2% below its estimated fair value. The current EV-to-EBITDA is 18.74, which is 19% below median its 10-year median of 23.12 and 35.4% above the Medical Devices & Instruments industry median of 13.85. Sartorius AG's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sartorius AG (SARTF), the current EV-to-EBITDA is 18.74 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 14.2% below its estimated GF Value™ of $248.02.
GuruFocus considers Sartorius AG to be Fairly Valued.
Key valuation signals for SARTF:
EV-to-EBITDA: 18.74 (19% below median its 10-year median of 23.12)
GF Value™: $248.02 vs. price of $212.80 (14.2% below fair value)
Industry Position: 35.4% above the Medical Devices & Instruments median (#338 of 510)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
83GF Score
Get the complete analysis for SARTF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
